ReShape Lifesciences Soars 52.58% on Patent Wins

On April 21, 2025, ReShape Lifesciences surged 52.58% in pre-market trading, marking a significant rise in its stock price.

ReShape Lifesciences has recently received a Notice of Allowance for an additional U.S. patent related to its proprietary diabetes neuromodulation technology. This patent, when issued, will provide protection until August 4, 2037, and is expected to strengthen the company's intellectual property portfolio. The patent covers the Diabetes Neuromodulation system, which leverages the company's proprietary vagus nerve block (vBloc™) technology.

The new patent is part of ReShape's ongoing efforts to enhance its diabetes treatment solutions. The energy-efficient technology could potentially reduce treatment costs for Type 2 diabetes, making it a significant development for the company and its stakeholders. This patent strengthens ReShape's position in the market and could attract more investors, contributing to the recent surge in its stock price.

Additionally, ReShape Lifesciences has been granted a key international patent in Israel for its proprietary diabetes neuromodulation technology. This international recognition further solidifies the company's innovative approach to diabetes treatment and expands its global reach. The combination of these patents and the company's technological advancements positions ReShape Lifesciences as a leader in the diabetes treatment market.